Moleculin Biotech CS (MBRX)

$0.43 -0.02 (-4.43%)
Market Cap 22.47M
Revenue (ttm) 0.00
Net Income (ttm) -21.76M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,295,800
Avg Vol 3,728,954
Day's Range N/A - N/A
Shares Out 49.50M
Stochastic %K 10%
Beta 1.57
Analysts Strong Sell
Price Target $6.67

Company Profile

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to...

Industry: Biotechnology
Sector: Healthcare
Phone: (713) 300-5160
Address:
5300 Memorial Drive, Suite 950, Houston, United States
IVALTE
IVALTE Nov. 14 at 9:50 PM
$MBRX and here are people saying that it reach $4.X already...
0 · Reply
e04
e04 Nov. 14 at 7:35 PM
$MBRX 1500% to it’s target price But this stock is not doing good recent year And if it don’t goes up to $1 before December 24, it will be kick out by the NASDAQ High pay high risk.
0 · Reply
Stormra
Stormra Nov. 14 at 2:26 PM
$MBRX What's happening?
0 · Reply
Healthpro
Healthpro Nov. 13 at 11:21 PM
$MBRX positive news, it goes down. Negative news, it goes down. When is this thing going to go up?
0 · Reply
e04
e04 Nov. 13 at 9:25 PM
$MBRX what is the 10-Q Quarterly report?
0 · Reply
Stormra
Stormra Nov. 13 at 7:36 PM
$MBRX If you do not like a Stock Why do you hang out on its page and trash it. Asking for a friend.
0 · Reply
kpasch8
kpasch8 Nov. 13 at 6:59 PM
$MBRX take Wainwright's target and divide it by 3 then add 4%
0 · Reply
e04
e04 Nov. 13 at 6:39 PM
$MBRX will the financial report be great?
0 · Reply
Struin
Struin Nov. 13 at 4:34 PM
$MBRX Should bought today instead yesterday oef
0 · Reply
newbulloh2
newbulloh2 Nov. 13 at 4:28 PM
$MBRX quadruple bottom just delist already
0 · Reply
Latest News on MBRX
Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented

Nov 13, 2025, 8:36 AM EST - 1 day ago

Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented

Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill

Nov 12, 2025, 8:37 AM EST - 2 days ago

Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill

Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial at the 14th Annual Acute Leukemia Meeting

Oct 30, 2025, 8:40 AM EDT - 15 days ago

Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial at the 14th Annual Acute Leukemia Meeting

Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin

Oct 29, 2025, 8:35 AM EDT - 16 days ago

Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin

Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer

Oct 23, 2025, 8:00 AM EDT - 22 days ago

Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer

Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin

Sep 25, 2025, 8:35 AM EDT - 7 weeks ago

Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin

Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial

Sep 9, 2025, 8:45 AM EDT - 2 months ago

Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial

Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia

Sep 8, 2025, 8:30 AM EDT - 2 months ago

Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia

Moleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds

Aug 28, 2025, 8:30 AM EDT - 2 months ago

Moleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds

Moleculin Issues New Positive AML Overall Survival Data:

Aug 27, 2025, 8:45 AM EDT - 2 months ago

Moleculin Issues New Positive AML Overall Survival Data:

Moleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 14, 2025, 9:15 AM EDT - 3 months ago

Moleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Moleculin Reports Second Quarter 2025 Financial Results and Highlights

Aug 13, 2025, 8:05 AM EDT - 3 months ago

Moleculin Reports Second Quarter 2025 Financial Results and Highlights

Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment

Aug 6, 2025, 8:40 AM EDT - 3 months ago

Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment

Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin

Jul 30, 2025, 8:35 AM EDT - 3 months ago

Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin

Moleculin Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 22, 2025, 8:45 AM EDT - 4 months ago

Moleculin Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships

Jul 17, 2025, 8:25 AM EDT - 4 months ago

Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships

Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans

Jul 9, 2025, 8:35 AM EDT - 4 months ago

Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans

Moleculin Announces $5.9 Million Public Offering

Jun 20, 2025, 9:20 AM EDT - 5 months ago

Moleculin Announces $5.9 Million Public Offering

Moleculin Participates in Virtual Investor “What This Means” Segment

Jun 18, 2025, 7:45 AM EDT - 5 months ago

Moleculin Participates in Virtual Investor “What This Means” Segment

Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML

Jun 18, 2025, 7:30 AM EDT - 5 months ago

Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML

Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107)

Jun 5, 2025, 8:00 AM EDT - 5 months ago

Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107)

Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)

Jun 4, 2025, 8:45 AM EDT - 5 months ago

Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)

Moleculin Biotech, Inc. (MBRX) Q1 2025 Earnings Call Transcript

May 14, 2025, 12:20 PM EDT - 6 months ago

Moleculin Biotech, Inc. (MBRX) Q1 2025 Earnings Call Transcript

Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 7:30 AM EDT - 6 months ago

Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update

Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial

May 12, 2025, 8:40 AM EDT - 6 months ago

Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial

Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast

May 7, 2025, 9:00 AM EDT - 6 months ago

Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast

Moleculin Announces World Health Organization Approval of “naxtarubicin” as International Non-Proprietary Name for Annamycin

May 6, 2025, 9:00 AM EDT - 6 months ago

Moleculin Announces World Health Organization Approval of “naxtarubicin” as International Non-Proprietary Name for Annamycin

Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents

May 5, 2025, 8:45 AM EDT - 6 months ago

Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents

Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer

Apr 29, 2025, 8:35 AM EDT - 7 months ago

Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer

Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

Apr 17, 2025, 8:30 AM EDT - 7 months ago

Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial

Apr 1, 2025, 8:30 AM EDT - 8 months ago

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial

Moleculin Biotech, Inc. (MBRX) Q4 2024 Earnings Call Transcript

Mar 24, 2025, 10:50 AM EDT - 8 months ago

Moleculin Biotech, Inc. (MBRX) Q4 2024 Earnings Call Transcript

Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 24, 2025, 7:05 AM EDT - 8 months ago

Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update

Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast

Mar 19, 2025, 8:05 AM EDT - 8 months ago

Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast

Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

Mar 11, 2025, 8:45 AM EDT - 8 months ago

Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

Moleculin to Present at the 37th Annual ROTH Conference

Mar 10, 2025, 8:45 AM EDT - 8 months ago

Moleculin to Present at the 37th Annual ROTH Conference

Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity

Mar 6, 2025, 8:30 AM EST - 9 months ago

Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity

Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium

Mar 3, 2025, 8:30 AM EST - 9 months ago

Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium

Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules

Feb 25, 2025, 12:35 PM EST - 9 months ago

Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules

Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday?

Feb 13, 2025, 1:19 PM EST - 9 months ago

Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday?

Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds

Feb 13, 2025, 1:05 PM EST - 9 months ago

Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds

Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML)

Feb 13, 2025, 9:25 AM EST - 9 months ago

Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML)

Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial

Feb 11, 2025, 8:40 AM EST - 9 months ago

Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial

Moleculin Participates in Virtual Investor "What This Means" Segment

Jan 27, 2025, 8:30 AM EST - 10 months ago

Moleculin Participates in Virtual Investor "What This Means" Segment

Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026

Jan 8, 2025, 8:30 AM EST - 11 months ago

Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026

Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model

Dec 11, 2024, 8:00 AM EST - 1 year ago

Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model

New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML

Nov 18, 2024, 8:15 AM EST - 1 year ago

New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML

Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025

Nov 14, 2024, 8:15 AM EST - 1 year ago

Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025

Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)

Nov 12, 2024, 8:00 AM EST - 1 year ago

Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)

Moleculin Biotech, Inc. (MBRX) Q3 2024 Earnings Call Transcript

Nov 11, 2024, 11:17 AM EST - 1 year ago

Moleculin Biotech, Inc. (MBRX) Q3 2024 Earnings Call Transcript

IVALTE
IVALTE Nov. 14 at 9:50 PM
$MBRX and here are people saying that it reach $4.X already...
0 · Reply
e04
e04 Nov. 14 at 7:35 PM
$MBRX 1500% to it’s target price But this stock is not doing good recent year And if it don’t goes up to $1 before December 24, it will be kick out by the NASDAQ High pay high risk.
0 · Reply
Stormra
Stormra Nov. 14 at 2:26 PM
$MBRX What's happening?
0 · Reply
Healthpro
Healthpro Nov. 13 at 11:21 PM
$MBRX positive news, it goes down. Negative news, it goes down. When is this thing going to go up?
0 · Reply
e04
e04 Nov. 13 at 9:25 PM
$MBRX what is the 10-Q Quarterly report?
0 · Reply
Stormra
Stormra Nov. 13 at 7:36 PM
$MBRX If you do not like a Stock Why do you hang out on its page and trash it. Asking for a friend.
0 · Reply
kpasch8
kpasch8 Nov. 13 at 6:59 PM
$MBRX take Wainwright's target and divide it by 3 then add 4%
0 · Reply
e04
e04 Nov. 13 at 6:39 PM
$MBRX will the financial report be great?
0 · Reply
Struin
Struin Nov. 13 at 4:34 PM
$MBRX Should bought today instead yesterday oef
0 · Reply
newbulloh2
newbulloh2 Nov. 13 at 4:28 PM
$MBRX quadruple bottom just delist already
0 · Reply
CrisMars
CrisMars Nov. 13 at 3:17 PM
$MBRX in yesterday and out today…
0 · Reply
CrisMars
CrisMars Nov. 13 at 3:16 PM
$MBRX truly disappointed…now the phase 3 data is next year, not Q4-2025. that push back ti 2026 is against their previous promise of this year…
0 · Reply
Stormra
Stormra Nov. 13 at 3:10 PM
$MBRX Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented Globe Newswire 1 hour ago Completion of treatment for the first 45 patients on pace for Q1 2026 with initial unblinded data thereafter; blinded response activity tracking within expected range
0 · Reply
merlin8121
merlin8121 Nov. 13 at 11:46 AM
$MBRX New report out : https://www.merlintrader.com/biotech-fury/
0 · Reply
YanstersParadise
YanstersParadise Nov. 13 at 12:40 AM
$MBRX
0 · Reply
MessiMagic
MessiMagic Nov. 12 at 10:16 PM
$MBRX Phase 3 MIRACLE trial data readout for relapsed/refractory acute myeloid leukemia (r/r AML) patients, expected in the fourth quarter of 2025.
0 · Reply
MessiMagic
MessiMagic Nov. 12 at 10:15 PM
$MBRX Analyst Sara Nik from H.C. Wainwright reiterated a Buy rating on the stock and has a $4.00 price target.
0 · Reply
Struin
Struin Nov. 12 at 8:59 PM
$MBRX and another 5000
0 · Reply
Struin
Struin Nov. 12 at 6:53 PM
$MBRX Bought 5000 today
0 · Reply
Stormra
Stormra Nov. 12 at 5:37 PM
$MBRX
0 · Reply
CrisMars
CrisMars Nov. 12 at 5:04 PM
$MBRX finally a real US top tier deal.…I am back in for sure. UNC is an entryway to big pharma and patient level 1 and significant market expansion. MBRX will release positive phase 3 results before year end. couple that with investigations like this and a substantial stock rise is imminent.
0 · Reply
MessiMagic
MessiMagic Nov. 12 at 3:21 PM
$MBRX Great news!!! You must be patience with this company. Don’t get misled by day traders manipulating the volume of this stock. For them this is a great stock price to buy large quantities increase value, send manipulating messages, get others to buy and then sell everything within the end of day or next day. You can clearly see this when you look the last 30 days activity.
0 · Reply